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Iron is an essential trace element subject to tight regulation to ensure adequate running 
of biological processes. In sub-Saharan Africa where hemoglobinopathies are common, 
iron homeostasis is likely to be impaired by these conditions. Here, we assessed and 
compared key serum proteins associated with iron metabolism between sub-Saharan 
African children with sickle cell disease (SCD) and their unaffected siblings. Complete 
blood counts and serum concentrations of four key proteins involved in iron regulation 
(ferritin, transferrin, sTfR, and hepcidin) were measured for 73 children with SCD and 68 
healthy siblings in Benin, West Africa. We found significant differences in concentration 
of transferrin, sTfR, and ferritin between the two groups. Hepcidin concentrations were 
found at unusually high concentrations but did not differ among the two groups. We 
found a significant negative correlation between hepcidin levels and both MCH and MCV 
in the SCD group and report that sTfR concentrations show a correlation with MCV and 
MHC in opposite directions in the two groups. These results highlight the unusually high 
levels of hepcidin in the Beninese population and the patterns of differential iron homeo-
stasis taking place under SCD status. These results lay the foundation for a systematic 
evaluation of the underlying mechanisms deregulating iron homeostasis in populations 
with SCD or high prevalence of iron deficiency.
Keywords: iron homeostasis, sickle cell disease, anemia, iron deficiency, hepcidin, serum iron proteins, red blood 
cell indices
inTrODUcTiOn
Sickle cell disease (SCD), an inherited disorder of hemoglobin (Hb) structure, is one of the most com-
mon severe disorders in the world (1). In 2010, sub-Saharan Africa accounted for two-third of SCD 
births worldwide, making it the most burdened region (2). In Benin, the under-five mortality rate 
of SCD was estimated at 15.5/1,000 in a cohort of patients benefiting from a tailored comprehensive 
clinical care program (CCCP) (3). SCD can also lead to severe complications in affected individuals, 
including significant homeostasis imbalance. Furthermore, imbalance in iron metabolism could be 
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more accentuated in area where iron deficiency is a large health 
problem, such as in Benin (4, 5). Thus, it is of interest to study 
the patterns of iron homeostasis in a context in which both iron 
deficiency and SCD are common.
Regulation of iron supply is essential to ensure adequate run-
ning of biological processes, such as erythroid function, binding 
and transport of oxygen as well as cellular respiration, and DNA 
synthesis and reparation (6, 7). Iron deficiency in early childhood 
is associated with numerous adverse health effects, including 
immune, neurological, and cognitive development impairments 
that may be irreversible even after iron repletion (8, 9). Similarly, 
excess of iron is deleterious for health and has become a major 
cause of morbidity and premature mortality (10, 11). The total 
iron store in the human body is approximately 3–4 g and is mainly 
distributed in the Hb of mature red blood cells and developing 
erythroid cells. In normal conditions 1–2 mg of iron is absorbed 
daily and an equivalent amount is lost. There is no physiological 
system for iron elimination; however, iron metabolism, storage, 
and transport are tightly regulated by a key set of proteins (12, 
13). The regulation of iron homeostasis depends on a complex 
feedback mechanism between body iron requirements and 
intestinal absorption. Thus, iron stores are subject to tight control 
from intake in the intestine to storage, turnover, redistribution, 
and mobilization in the body (13, 14).
In the last decades, there have been tremendous advances in 
deciphering the mechanisms of iron homeostasis in the body 
and the understanding of the interplay between serum proteins 
implicated in this process. Of these proteins, hepcidin, a small 
25-amino-acid peptide, produced mainly by hepatocytes and 
secreted into the blood has been recognized as a key regulator 
in homeostasis. (15–17). Other key iron metabolism proteins in 
the serum include ferritin, transferrin, and soluble transferrin 
protein (sTfR). Polymorphisms in these proteins could affect 
iron metabolism (18, 19). However, such genetic variants have 
not been documented in Benin.
In this study, we compared key parameters of iron homeo-
stasis between children with SCD (cases) and their unaffected 
siblings (control group) in the Republic of Benin, West Africa. 
We assessed and compared relevant hematological indicators and 
the serum proteins directly linked to iron metabolism between 
the two groups and evaluated the relationship between these 
hematological indicators and the serum iron proteins.
MaTerials anD MeThODs
subjects
A total of 141 children were enrolled in our study in 2010, 
including 73 children with SCD. These children were part of a 
large cohort of early diagnosis for SCD and CCCP (20) at the 
“Centre de Prise en charge Médicale Intégrée du Nourrisson et 
de la Femme Enceinte atteints de Drépanocytose” (CPMI-NFED) 
(National Institute dedicated to caring of Infants and Pregnant 
Women affected by SCD) in Cotonou, The Republic of Benin. 
The CCCP includes an intensive socio-medical intervention 
program that aims to diagnose SCD early and to attenuate the 
effects of the disease on children as they grow up. As part of the 
clinical follow-up program children orally received powdered 
generic containing 5 mg/kg/day of elemental iron with orange or 
lemon juice 30 min before meals. This iron supplementation was 
provided every 9 months for a period of 2 months. All children 
with SCD were sampled at least 1 month after they finished their 
iron supplementation regime and none of the unaffected children 
were taking iron during the course of the study. Of the 73 chil-
dren with SCD, 15 were diagnosed with acute anemia and were 
transfused during the 4 months preceding sampling of which 8 
were transfused once, two twice, one three time, and one six time. 
The control group consisted of 68 age-matched siblings of the 
recruited children with SCD. Approval for the study was obtained 
from the Ethical Committee of the Faculty of Health Sciences.
Procedures
Children with SCD were enrolled in the study after informed 
consent was obtained. All children were sampled under steady 
state during regular follow-up visits in the morning between 
8:00 and 11:00 a.m. Based on clinical assessment, age-matched 
unaffected siblings, without any history of acute illness at least 
3 months prior to sampling, were brought by parents for sampling 
after informed consent was obtained. Complete blood counts 
(CBC) were immediately performed using an automatic blood 
cell analyzer (KX-21, Sysmex Corporation, Japan) (Table S1 in 
Supplementary Material). Sera were frozen and stored at −30°C 
for subsequent measurement of ferritin, transferrin, sTfR, and 
hepcidin.
Serum ferritin, transferrin, sTfR, and hepcidin concentrations 
were measured using their respective ELISA kits following the 
manufacturers’ recommended protocols: IBL International 
GMBH, Hamburg, Germany, for ferritin and Hepcidin and 
Prohormone, Modrice, Czech Republic, for transferrin and 
sTfR (Table S1 in Supplementary Material). The sTfR index 
was calculated as the ratio of log (sTfR) (nanogram/milliliter) 
to the log (serum ferritin) (nanogram/milliliter) as previously 
described (21). The reference ranges for iron homeostasis serum 
proteins indicating normal iron status were defined as follow: 
25–283  ng/L for ferritin, 2–5  g/L for transferrin, 0.9–3.4  μg/
mL for sTfR, 58.9–158.1 ng/mL for hepcidin, and 1.5 for the log 
(sTfR)/log (ferritin) ratio (22). For Hb, we used the pediatric cut 
off value defined by the World Health Organization (WHO) (23). 
The cut off values for the red blood cell indices were as follow: 
MCH < 25 pg and MCV < 75 fL.
Data statistical analysis
Quantitative data were analyzed using Kruskal–Wallis, Wilcoxon 
and median non-parametric tests. A linear regression model was 
used to test for differential association in SCD patients and the 
control group between key hematological parameters and the 
assayed iron regulation proteins. Sex and age were included in 
regression analyses as covariates. These analyses test the hypoth-
esis that proteins directly involved in iron homeostasis are (a) dif-
ferentially regulated between SCD patients and their unaffected 
siblings and (b) influence iron homeostasis through regulation 
of MCH and MCV, two of the indices most correlated with iron 
regulation in the body. Hypothesis (a) was tested by compar-
ing the mean and variance of the concentration of the assayed 
TaBle 2 | hematological values in steady-state scD patients and the 
controls.
indicators scD patients, 
mean ± sD
controls, 
mean ± sD
p-value
Hemoglobin concentration (g/L) 87.8 ± 15.8 110.0 ± 9.0 <0.0001
MCV (fL) 79.2 ± 8.2 73.6 ± 6.1 <0.0001
MCH (pg) 25.0 ± 2.8 23.2 ± 2.4 <0.0001
TaBle 1 | characteristics of the study subjects.
scD patients controls
Patients, n (%) 73 (100%) 68 (100%)
Male gender 43 (58.9%) 32 (47.1%)
Female gender 30 (41.1%) 36 (52.9%)
Median age, month (range) 36 (12–72) 33.5 (6–72)
hemoglobin (hb) type, n (%)
HbSS 53 (72.6%) 0
HbSC 20 (27.4%) 0
HbAA 0 30 (30.9%)
HbAS 0 45 (66.2%)
HbAC 0 2 (2.9%)
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proteins between SCD patients and the controls. Hypothesis (b) 
was tested by comparing the relationship between both MCH 
and MCV, as dependent variables, and the assayed proteins in 
the SCD and control groups.
resUlTs
subject characteristics
A total of 141 children, 73 SCD patients with Hb genotypes SS 
(53) or SC (20) and 68 unaffected siblings with Hb genotypes AA 
(21), AS (45), or AC (2) were recruited. The demographic, gender, 
and Hb characteristics of both groups are listed in Table 1. Age 
and sex distributions were not significantly different between the 
two groups (p = 0.1518 and p = 0.1595, respectively).
hematological Profiles
Hematological details of patients in the steady state and controls 
are summarized in Table 2. As expected, the mean Hb concentra-
tion was significantly lower (p < 0.0001) in children with SCD 
(87.8 g/L) compared to the control group (110.0 g/L) with 87.7% 
of children having Hb values below the normal distribution. We 
note that in the control group 20.4% of children had a mean 
Hb concentration below the WHO’s threshold defining anemia 
in the corresponding age group (23). We also note that mean 
concentration for both red blood cell indices MCV and MCH 
were significantly reduced in the control group (p < 0.001) as 54 
and 85% of children in the control group had MCV and MCH 
values below the cut off value of 75 fL and 25 pg, compared to 30 
and 52% in the SCD group, respectively.
serum iron Protein Profiles in the control 
and scD groups
Mean concentrations of transferrin, sTfR, ferritin, and the log 
(sTfR)/log (ferritin) index were statistically different (p < 0.001) 
between the SCD and control groups but hepcidin (p = 0.6487, 
Table 3). Testing for equal variances between SCD and control 
groups for the four proteins revealed that variance was signifi-
cantly different except for hepcidin (Figure 1). In particular, we 
note the extreme case of ferritin that shows striking difference in 
variance between the two groups (Figure 1).
The mean values of transferrin and the log (sTfR)/log (fer-
ritin) index were within the normal range (2–5  g/L and ≥1.5, 
respectively) in children with SCD (4.1 g/L and 5.9, respectively) 
whereas both were above the upper limit of normal values in the 
control group (6.9 g/L and 1.8, respectively). In addition, 67 and 
79% of individuals in the control group have transferrin and sTfR 
index concentrations above the cut off. By contrast, in children 
with SCD, ferritin and sTfR levels were almost twofold above the 
upper limit of normal ferritin and sTfR (558.9 ng/L for ferritin 
and 5.9 μg/mL for sTfR), while in the control group both con-
centrations were within the normal ranges (59.0 ng/L for ferritin 
and 2 μg/mL for sTfR). We also compared ferritin concentration 
levels between SCD children with past history of blood transfu-
sions and those who have never been transfused. The mean fer-
ritin concentrations were not significantly different (p = 0.1072) 
between transfused and non-transfused children, suggesting 
that blood transfusion does not explain the observed high level 
of ferritin in children with SCD (Figure 1 in Supplementary 
Material). Finally, intriguingly in both SCD and control groups, 
mean hepcidin concentration were unexpectedly high (231.6 and 
225.6 ng/mL, respectively) and above the upper limit of normal 
hepcidin values of 58.9–158.1 ng/mL. We should also note that 
within the control group, mean transferrin concentrations were 
found to be significantly different between AA and AS/C geno-
types (p = 0.006) (Figure 2 in Supplementary Material).
correlation between the Four iron 
homeostasis serum Proteins and McV 
and Mch
We performed multiple regression analyses to examine the 
relationship between the four serum iron proteins and MVC and 
MCH levels in SCD and control groups. First, we constructed 
a multivariate statistical model that includes all four serum 
proteins assayed against MCV or MCH. The predicted against 
actual Y plots (Figures 2 and 3) show that the models fit best in 
the SCD group (p = 0.0004 and p = 0.0107, respectively) relative 
to the control group where the fit is not statistically significant 
(p =  0.2439 and p =  0.4725, respectively). Univariate analyses 
showed that hepcidin concentrations were negatively correlated 
with MCV and MCH levels in the SCD group (Pearson correlation 
r2 = 0.1502, p = 0.0007 and r2 = 0.0167, p = 0.0005, respectively, 
Figures 2 and 3). Also, sTfR concentrations show opposite trends 
in the two groups being negatively correlated with MCV and MCH 
in the control group (r2 = 0.0946, p = 0.0127 and r2 = 0.0915, 
p = 0.0143, respectively) and positively correlated with MCV and 
MCH in the SCD group (r2 = 0.1593, p = 0.0005 and r2 = 0.0283, 
p = 0.1548, respectively) (Figures 2 and 3). We note that trans-
ferrin and ferritin show the same trend as sTfR in both groups 
but it is not statistically significant (Figure 3 in Supplementary 
Material). These findings show that the association between key 
FigUre 1 | comparisons of means and variances of the four iron serum proteins in the control and scD groups. right panel: the diamonds show the 
95% confidence intervals and the horizontal black line shows the mean value across the entire set of individuals. left panel: the densities show the distribution of 
each protein in the control and SCD groups.
TaBle 3 | iron homeostasis serum proteins profiles in scD patients in the steady state and in controls.
Proteins scD patients controls p-valuec
Mean ± sD subjects with values 
above the cut-offa, n (%)
Median/
interquartile rangeb
Mean ± sD Median/
interquartile rangeb
subjects with values 
above the cut-offa, n (%)
Transferrin (g/L) 4.1 ± 1.5 16 (21.9) – 6.9 ± 3.1 – 46 (67.6) <0.0001
sTfR (μg/mL) 5.9 ± 2.2 56 (76.7) – 1.8 ± 0.7 – 5 (6.8) <0.0001
Ferritin (ng/L) 558.9 ± 434.7 48 (65.8) 445.6/(174.8−933.3) 44.0 ± 28.9 37.6/(24.3−54.5) 0 <0.0001
sTfR index 1.5 ± 0.3 25 (34.2) – 2.1 ± 0.9 – 58 (79.4) <0.0001
Hepcidin (ng/mL) 231.6 ± 128.2 47 (64.4) 215.2/(127.3−287.4) 225.6 ± 135.1 192.9/(130.3−296.9) 41 (56.2) 0.6487
aCut-off values defined in Section “Materials and Methods.”
bMedian and interquartile range for non-normally distributed proteins ferritin and hepcidin.
cWilcoxon test, means comparisons.
February 2016 | Volume 4 | Article 84
Gomez et al. Iron in Sickle Cell Disease
Frontiers in Pediatrics | www.frontiersin.org
FigUre 2 | association of hepcidin and sTfr with McV in the control and scD groups. (a) Full multivariate models (control group, left panel, and SCD 
group, right panel). (B,c) Univariate models testing the association of each protein (control group, left panels, and SCD group, right panel). The red solid line shows 
the line of fit, the red dashed line represents the 95% confidence curves and the blue dashed line shows the horizontal mean reference that represents the null 
hypothesis.
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hematological indicators (i.e., MCH and MCV) and hepcidin and 
sTfR is altered under the SCD condition.
To test for the effect of blood transfusion of the observed 
differences, we removed from the analysis the study participants 
who received blood transfusion and observed no significant dif-
ferences in the results. To test for differences between genotypic 
classes within the control group, we performed the association 
tests by genotype (AA and AS/C groups). Of the four proteins 
investigated and although not statistically significant, hepcidin 
and ferritin concentrations showed two opposite trends in 
the two groups, being positively correlated with MCV and 
MCH in the AA group and negatively correlated in the AS/C 
group (Figure 4 in Supplementary Material). These findings 
demonstrate that the observed differences in hepcidin and fer-
ritin between the SCD and control groups detailed above are 
more pronounced when SCD patients are compared to the AA 
genotype group.
DiscUssiOn
Sickle cell disease is common throughout much of sub-Saharan 
Africa. In Benin, SCD is associated with high rate of childhood 
mortality and morbidity (3). Although many aspects of SCD 
are studied, reports on proteins involved in iron homeostasis in 
children with SCD are scarce. Given the above, we conducted 
this study to document the patterns of iron metabolism in young 
FigUre 3 | association of hepcidin and sTfr with Mch in the control and scD groups. (a) Full multivariate models (control group, left panel, and SCD 
group, right panel). (B,c) Univariate models testing the association of each protein (control group, left panels, and SCD group, right panel). The red solid line shows 
the line of fit, the red dashed line represents the 95% confidence curves and the blue dashed line shows the horizontal mean reference that represents the null 
hypothesis.
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children with and without SCD by examining hematological 
indices and four key serum iron metabolism-associated proteins.
The hematological indices assessed closely in our study are Hb, 
MCV, and MCH. Subjects with SCD had significantly lower levels 
of Hb compared to the controls. This observation was expected 
considering the physiopathology of the disease. We also note that 
20.4% control children had Hb levels below the normal range 
but this was not associated with the sickle cell trait phenotype. 
In contrast to other reports (24, 25), SCD subjects in our study 
had higher levels of RBC indices compared to the control group. 
This observation could be due to the effect of the follow-up clini-
cal program, part of which children take iron supplements (13). 
These low values could be explained partly by iron deficiency, one 
of the main causes of anemia (26, 27). Rahimy et al. (5) previ-
ously showed that iron deficiency was a predominant condition 
in healthy young children in Benin. Our results are consistent 
with this finding, suggesting that the hematological levels in our 
control group are in line with the hematological profiles reported 
in the general pediatric population in Benin.
To assess the effect of SCD status on indicators and parameters 
associated with iron homeostasis (22, 28, 29), we compared the 
concentration of four serum iron proteins (transferrin, ferritin, 
sTfR, and hepcidin) and the log (sTfR)/log (ferritin) index 
between SCD subjects and controls. Iron balance is regulated by 
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modulating the rate of erythropoiesis and by the amount of iron 
stores (30). When iron is deficient, the concentration of transferrin 
and sTfR increases, while that of ferritin synthesis and hepcidin 
declines (31, 32). In contrast to the control group, the SCD group 
had elevated concentrations of ferritin and sTfR and lower levels 
of transferrin and log (sTfR)/log (ferritin) index. Such elevated 
concentrations of ferritin and sTfR are usually associated with 
iron overload and have been reported in the case of blood transfu-
sion (33, 34). However, this scenario is unlikely in our study as we 
do not observe a significant association between blood transfu-
sion history and ferritin concentration in our cohort, suggesting 
the presence of an excess of intravascular hemolysis causing an 
increase of iron absorption as previously reported (35). Elevated 
levels of ferritin contrasted with normal levels of transferrin and 
sTfR and a normal log (sTfR)/log (ferritin) index. This observa-
tion is intriguing and warrants further investigation to unravel 
the underlying mechanisms.
Intriguingly, we observed high levels of hepcidin in both 
SCD group and controls with approximately 65 and 56% of 
individuals in SCD and control group, respectively, showing 
hepcidin levels above the upper limit of the normal range. This 
observation suggests that the high level of hepcidin is a com-
mon trait in Beninese children. We also observed a significant 
negative correlation between hepcidin levels and both MCH 
and MCV only in the SCD group and an opposite trend for 
sTfR and both MCH and MCV in the control group (negative 
correlation) and in the SCD group (positive correlation). We 
also assessed the potential effect of sickle cell trait genotype on 
iron homeostasis proteins by stratifying the control group by 
genotype (AA versus AS/C) in our association analysis. Several 
studies have highlighted the link between SCD trait genotypes 
and conditions, such as systemic inflammation (36) and oxida-
tive stress (37). Our results show differences between AA and 
AS/C genotypes and demonstrate that the opposite trends 
observed for hepcidin and ferritin between SCD patients and 
the controls are driven by the AA individuals. Normal to low 
levels of hepcidin in SCD have been previously reported (38, 
39). However, our results do not support the generalization of 
these findings. This observation hints to the possibility that 
the effect of other variables modulating the production of 
hepcidin might be in play in our cohort or in West African 
populations in general as indicated by the unusually high 
levels of hepcidin even in the unaffected group. High levels of 
hepcidin under severe iron deficiency have only been reported 
in pathological conditions, such as rare hepatic adenomas and 
familial iron-refractory iron deficiency anemia (40, 41). In 
our study population, it is unlikely that the observed patterns 
results from pathological conditions, given our knowledge of 
medical history of the study subjects and given that the trend 
is observed in both disease and control groups. The observed 
relationship between hepcidin and MCH and MCV in popula-
tions such as Benin where iron deficiency is prevalent can also 
be modulated by diet and/or selective pressure to maintain low 
levels of iron in the body against infectious agents that require 
high levels of iron (42–45). We hypothesize that these factors 
contribute to the negative correlation we observe between 
hepcidin and both MCH and MCV, an effect exacerbated 
under SCD status. However, further investigations are required 
to confirm these hypotheses. Our study also highlights the 
unusually high levels of hepcidin in the Beninese population 
and the differential patterns of iron homeostasis through the 
association between hepcidin levels and key hematological 
parameters. Furthermore, SCD patients are more likely to suf-
fer from nutritional deficiencies caused by increased metabolic 
requirements (46, 47). Polymorphisms in genes coding for iron 
regulation proteins can also modulate the mechanisms of iron 
metabolisms (48). Future studies should account for these vari-
ables that can alter the expression and/or function of the key 
iron metabolism proteins.
These results lay the foundation for a systematic evaluation 
of the underlying mechanisms deregulating iron homeostasis in 
populations with SCD or high prevalence of iron deficiency.
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